Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Files for 12M Secondary Offering

NEW YORK (GenomeWeb News) – Bruker has filed with the US Securities and Exchange Commission for a secondary offering of 12 million shares of common stock by two members of the Laukien family not involved in the firm's business.

Bruker will not receive any of the proceeds from the sale of the stock through this offering, it noted.

The two members of the Laukien family who are selling these shares are Marc Laukien and Isolde Laukien-Kleiner, neither of which are involved with the firm's business other than being shareholders. Simultaneously with the secondary offering, Bruker Chairman, President, and CEO Frank Laukien has agreed to purchase privately from Marc Laukien 100,000 shares of the firm's common stock.

The underwriters have a 30-day option to purchase up to an additional 1.8 million shares of common stock to cover over-allotments.

The offering price has not been set yet. Bruker's shares closed Thursday on the Nasdaq at $10.02.

Filed under

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.